258 related articles for article (PubMed ID: 24149047)
41. Usefulness of negative and weak-diffuse pattern of SDHB immunostaining in assessment of SDH mutations in paragangliomas and pheochromocytomas.
Castelblanco E; Santacana M; Valls J; de Cubas A; Cascón A; Robledo M; Matias-Guiu X
Endocr Pathol; 2013 Dec; 24(4):199-205. PubMed ID: 24096807
[TBL] [Abstract][Full Text] [Related]
42. Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes.
Gill AJ; Benn DE; Chou A; Clarkson A; Muljono A; Meyer-Rochow GY; Richardson AL; Sidhu SB; Robinson BG; Clifton-Bligh RJ
Hum Pathol; 2010 Jun; 41(6):805-14. PubMed ID: 20236688
[TBL] [Abstract][Full Text] [Related]
43. Updates on the genetics and the clinical impacts on phaeochromocytoma and paraganglioma in the new era.
Pillai S; Gopalan V; Smith RA; Lam AK
Crit Rev Oncol Hematol; 2016 Apr; 100():190-208. PubMed ID: 26839173
[TBL] [Abstract][Full Text] [Related]
44. [Hereditary pheochromocytoma-associated syndromes. Part 1].
Yukina MY; Troshina EA; Beltsevich DG
Ter Arkh; 2015; 87(9):102-105. PubMed ID: 26591561
[TBL] [Abstract][Full Text] [Related]
45. Heterogeneous genetic background of the association of pheochromocytoma/paraganglioma and pituitary adenoma: results from a large patient cohort.
Dénes J; Swords F; Rattenberry E; Stals K; Owens M; Cranston T; Xekouki P; Moran L; Kumar A; Wassif C; Fersht N; Baldeweg SE; Morris D; Lightman S; Agha A; Rees A; Grieve J; Powell M; Boguszewski CL; Dutta P; Thakker RV; Srirangalingam U; Thompson CJ; Druce M; Higham C; Davis J; Eeles R; Stevenson M; O'Sullivan B; Taniere P; Skordilis K; Gabrovska P; Barlier A; Webb SM; Aulinas A; Drake WM; Bevan JS; Preda C; Dalantaeva N; Ribeiro-Oliveira A; Garcia IT; Yordanova G; Iotova V; Evanson J; Grossman AB; Trouillas J; Ellard S; Stratakis CA; Maher ER; Roncaroli F; Korbonits M
J Clin Endocrinol Metab; 2015 Mar; 100(3):E531-41. PubMed ID: 25494863
[TBL] [Abstract][Full Text] [Related]
46. Transcription association of VHL and SDH mutations link hypoxia and oxidoreductase signals in pheochromocytomas.
Dahia PL;
Ann N Y Acad Sci; 2006 Aug; 1073():208-20. PubMed ID: 17102089
[TBL] [Abstract][Full Text] [Related]
47. Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas.
Gaal J; Burnichon N; Korpershoek E; Roncelin I; Bertherat J; Plouin PF; de Krijger RR; Gimenez-Roqueplo AP; Dinjens WN
J Clin Endocrinol Metab; 2010 Mar; 95(3):1274-8. PubMed ID: 19915015
[TBL] [Abstract][Full Text] [Related]
48. Denaturing high performance liquid chromatography detection of SDHB, SDHD, and VHL germline mutations in pheochromocytoma.
Meyer-Rochow GY; Smith JM; Richardson AL; Marsh DJ; Sidhu SB; Robinson BG; Benn DE
J Surg Res; 2009 Nov; 157(1):55-62. PubMed ID: 19215943
[TBL] [Abstract][Full Text] [Related]
49. Clinical and Molecular Features of Renal and Pheochromocytoma/Paraganglioma Tumor Association Syndrome (RAPTAS): Case Series and Literature Review.
Casey RT; Warren AY; Martin JE; Challis BG; Rattenberry E; Whitworth J; Andrews KA; Roberts T; Clark GR; West H; Smith PS; Docquier FM; Rodger F; Murray V; Simpson HL; Wallis Y; Giger O; Tran M; Tomkins S; Stewart GD; Park SM; Woodward ER; Maher ER
J Clin Endocrinol Metab; 2017 Nov; 102(11):4013-4022. PubMed ID: 28973655
[TBL] [Abstract][Full Text] [Related]
50. Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma.
Burnichon N; Vescovo L; Amar L; Libé R; de Reynies A; Venisse A; Jouanno E; Laurendeau I; Parfait B; Bertherat J; Plouin PF; Jeunemaitre X; Favier J; Gimenez-Roqueplo AP
Hum Mol Genet; 2011 Oct; 20(20):3974-85. PubMed ID: 21784903
[TBL] [Abstract][Full Text] [Related]
51. Increased expression of Nrf2 and elevated glucose uptake in pheochromocytoma and paraganglioma with SDHB gene mutation.
Kamai T; Murakami S; Arai K; Nishihara D; Uematsu T; Ishida K; Kijima T
BMC Cancer; 2022 Mar; 22(1):289. PubMed ID: 35300626
[TBL] [Abstract][Full Text] [Related]
52. Pheochromocytoma and functional paraganglioma syndrome: no longer the 10% tumor.
Elder EE; Elder G; Larsson C
J Surg Oncol; 2005 Mar; 89(3):193-201. PubMed ID: 15719371
[TBL] [Abstract][Full Text] [Related]
53. SDHD immunohistochemistry: a new tool to validate SDHx mutations in pheochromocytoma/paraganglioma.
Menara M; Oudijk L; Badoual C; Bertherat J; Lepoutre-Lussey C; Amar L; Iturrioz X; Sibony M; Zinzindohoué F; de Krijger R; Gimenez-Roqueplo AP; Favier J
J Clin Endocrinol Metab; 2015 Feb; 100(2):E287-91. PubMed ID: 25405498
[TBL] [Abstract][Full Text] [Related]
54. Genetic testing in pheochromocytoma or functional paraganglioma.
Amar L; Bertherat J; Baudin E; Ajzenberg C; Bressac-de Paillerets B; Chabre O; Chamontin B; Delemer B; Giraud S; Murat A; Niccoli-Sire P; Richard S; Rohmer V; Sadoul JL; Strompf L; Schlumberger M; Bertagna X; Plouin PF; Jeunemaitre X; Gimenez-Roqueplo AP
J Clin Oncol; 2005 Dec; 23(34):8812-8. PubMed ID: 16314641
[TBL] [Abstract][Full Text] [Related]
55. Uncommon clinical presentations of pheochromocytoma and paraganglioma in two different patients affected by two distinct novel VHL germline mutations.
Ercolino T; Becherini L; Valeri A; Maiello M; Gaglianò MS; Parenti G; Ramazzotti M; Piscitelli E; Simi L; Pinzani P; Nesi G; Degl'Innocenti D; Console N; Bergamini C; Mannelli M
Clin Endocrinol (Oxf); 2008 May; 68(5):762-8. PubMed ID: 18031321
[TBL] [Abstract][Full Text] [Related]
56. Familial pheochromocytoma.
Erlic Z; Neumann HP
Hormones (Athens); 2009; 8(1):29-38. PubMed ID: 19269919
[TBL] [Abstract][Full Text] [Related]
57. The genomic landscape of phaeochromocytoma.
Flynn A; Benn D; Clifton-Bligh R; Robinson B; Trainer AH; James P; Hogg A; Waldeck K; George J; Li J; Fox SB; Gill AJ; McArthur G; Hicks RJ; Tothill RW
J Pathol; 2015 May; 236(1):78-89. PubMed ID: 25545346
[TBL] [Abstract][Full Text] [Related]
58. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
[TBL] [Abstract][Full Text] [Related]
59. MAX mutations status in Swedish patients with pheochromocytoma and paraganglioma tumours.
Crona J; Maharjan R; Delgado Verdugo A; Stålberg P; Granberg D; Hellman P; Björklund P
Fam Cancer; 2014 Mar; 13(1):121-5. PubMed ID: 23743562
[TBL] [Abstract][Full Text] [Related]
60. Genotype-specific differences in the tumor metabolite profile of pheochromocytoma and paraganglioma using untargeted and targeted metabolomics.
Rao JU; Engelke UF; Sweep FC; Pacak K; Kusters B; Goudswaard AG; Hermus AR; Mensenkamp AR; Eisenhofer G; Qin N; Richter S; Kunst HP; Timmers HJ; Wevers RA
J Clin Endocrinol Metab; 2015 Feb; 100(2):E214-22. PubMed ID: 25459911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
